Karyopharm Therapeutics | KPTI - Gross Profit On Sales


Karyopharm Therapeutics reported $32.6M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Abbott USD 5.86B 675M Mar/2026
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
J&J USD 17.24B 642M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 11.04B 1.24B Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Takeda JPY 688.84B 101.71B Mar/2026
Tectonic Therapeutic USD 0 0 Mar/2025
TG Therapeutics USD 171.41M 16.98M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Xencor USD 21M 22.61M Sep/2025